Kovitz Investment Group Partners
MTNB icon

Kovitz Investment Group Partners’s Matinas BioPharma MTNB Stock Holding History

Kovitz Investment Group Partners’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-300
Closed -$12K – 420
2022
Q1 		$12K Buy
+300
New +$11K ﹤0.01% 414

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Kovitz Investment Group Partners's MTNB Position: Q2 2022 in Review

Kovitz Investment Group Partners sold out of Matinas BioPharma (MTNB) in Q2 2022, closing a stake of 300 shares — an estimated $12K sold.

Kovitz Investment Group Partners first reported a position in MTNB in Q1 2022 and held it in 1 quarter. The position peaked at $12K in Q1 2022. 50 funds tracked by Wall St. Rank hold MTNB as of Q2 2022.

  • Kovitz Investment Group Partners reported no remaining Matinas BioPharma position as of Q2 2022 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 300 Matinas BioPharma shares in Q2 2022, an estimated $12K.
  • Kovitz Investment Group Partners first reported a position in Matinas BioPharma in Q1 2022 and held it in 1 quarter.
  • Kovitz Investment Group Partners's Matinas BioPharma position peaked at $12K in Q1 2022.
  • 50 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2022.

Based on Kovitz Investment Group Partners's 13F filing for Q2 2022, filed 2 Aug 2022.